查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2076043

尿道感染治療市場：依藥物、適應症和地區分類－市場規模、佔有率、前景和機會分析，2025-2032年

Urinary Tract Infection Therapeutic Market, By Drug, By Indication, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032
出版日期: | 出版商: Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2026 年，尿道感染治療市場規模將達到 97.2 億美元，到 2033 年將達到 122.8 億美元。預計 2026 年至 2033 年的複合年成長率為 3.4%。

報告範圍 報告詳情
基準年： 2025 2026年市場規模： 97.2億美元
歷史數據時期： 2020年至2024年 預測期： 2026年至2033年
2026年至2033年預測期間的複合年成長率： 3.40% 2033年市場規模預測： 122.8億美元

尿道感染（UTI）是指泌尿系統任何部位所發生的感染疾病。女性罹患尿道感染感染的風險高於男性。泌尿道感染通常是由糞便中的細菌進入泌尿系統引起的。抗生素通常用於尿道感染的初始尿道感染。治療單純性尿道感染的常用藥物包括複方新諾明（甲氧芐啶和磺胺甲噁唑，商品名：Bactrim、Bactrim DS）、磷黴素（商品名：Monolol）、呋喃妥因（商品名稱：Macrodantin、Macrovid、Fladantin）、頭孢氨芐和頭孢曲松。

市場動態：

尿道感染的高發生率、糖尿病和腎結石盛行率的增加、老年人口的成長以及對開發新療法的日益重視，預計將成為預測期內推動全球尿道感染治療市場成長的主要因素。

2021年10月，Spero Therapeutics公司向美國食品藥物管理局（FDA）提交了替比培南氫溴酸鹽片的新藥認證（NDA），用於治療由敏感微生物引起的複雜性尿道感染（cUTI），包括腎盂腎炎。此外，2021年9月，BDR Pharma公司推出了比亞培南，用於治療腹腔內感染疾病、下呼吸道感染疾病或複雜性尿道感染。

2020 年 7 月，美國食品藥物管理局(FDA) 核准抗生素 Recarbrio（Imipenem、西司他丁、瑞巴坦）用於治療成人複雜性尿道感染(cUTI) 和複雜性腹腔內感染疾病(cIAI)。

本研究的主要特點：

  • 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
  • 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
  • 本研究根據公司概況、產品系列、主要亮點、財務表現和策略等參數，創建了全球尿道感染治療市場主要公司的概況。
  • 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
  • 這份《全球尿道感染治療市場》報告旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
  • 相關人員可以透過利用全球尿道感染治療市場分析中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

  • 分析目的
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

  • 市場動態
    • 全球範圍內，尿道感染的發生率正在上升。
    • 治療尿道感染藥物的副作用
    • 人們越來越關注新藥研發。
  • 影響分析
  • 主要亮點
  • 監管趨勢
  • 產品上市及核准
  • PEST分析
  • 波特的分析
  • 併購情景

第4章 全球尿道感染治療藥物市場：依藥物分類，2021-2033年

  • 青黴素聯合治療
  • 奎諾酮藥物
  • 頭孢菌素
  • 唑類藥物和Amphotericin B
  • 硝基呋喃類藥物
  • 其他藥物

第5章 全球尿道感染治療市場：依適應症分類，2021-2033年

  • 複雜性尿道感染
  • 單純性尿道感染
  • 其他改編

第6章 全球尿道感染治療市場：依地區分類，2021-2033年

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
  • 世界其他地區

第7章 競爭情勢

  • Pfizer
  • Novartis AG
  • Cipla Inc.
  • Bayer AG
  • AstraZeneca
  • Shionogi & Co. Ltd.
  • GlaxoSmithKline PLC

第8章 分析師建議

  • 機會分析
  • 分析師意見
  • Coherent Opportunity Map

第9章

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI1178

Urinary Tract Infection Therapeutic Market is estimated to be valued at USD 9.72 Bn in 2026 and is expected to reach USD 12.28 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.4% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 9.72 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 3.40% 2033 Value Projection: USD 12.28 Bn

A urinary tract infection (UTI) is an infection in any part of the urinary system. Women are at greater risk of developing a urinary tract infection compared to men. Urinary tract infections (UTIs) are usually caused by bacteria from poo entering the urinary tract. Antibiotics usually are the first treatment for urinary tract infections. Medicines commonly used for simple UTI s include Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS), Fosfomycin (Monurol), Nitrofurantoin (Macrodantin, Macrobid, and Furadantin), Cephalexin, and Ceftriaxone.

Market Dynamics:

High prevalence of urinary tract infection, increasing prevalence of diabetes and kidney stones, increasing geriatric population, and increase in focus on the development of novel therapeutics are some major factors expected to drive growth of the global urinary tract infection therapeutic market during the forecast period.

In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Moreover, in September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

In July 2020, the U.S. Food and Drug Administration (FDA) approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Key features of the study:

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global urinary tract infection therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global urinary tract infection therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary tract infection therapeutic market.

Detailed Segmentation:

  • Global Urinary Tract Infection Therapeutic Market By Drug (Revenue, USD Bn, 2021 - 2033)
  • Penicillin and Combinations
  • Quinolones
  • Cephalosporin
  • Azoles and Amphotericin B
  • Nitrofurans
  • Other Drugs
  • Global Urinary Tract Infection Therapeutic Market By Indication; (Revenue, USD Bn, 2021 - 2033)
  • Complicated UTI
  • Uncomplicated UTI
  • Other Indications
  • Regional Insights (Revenue, USD Bn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Company Profiles:
  • Pfizer
  • Novartis AG
  • Cipla Inc.
  • Bayer AG
  • AstraZeneca
  • Shionogi & Co. Ltd.
  • GlaxoSmithKline PLC

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Urinary Tract Infection Therapeutic, By Drug
    • Market Urinary Tract Infection Therapeutic, By Indication
    • Market Urinary Tract Infection Therapeutic, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • High prevalence of urinary tract infection across the globe
    • Adverse effects associated with the use of UTI medication
    • Increase in focus on the development of novel drugs
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Urinary Tract Infection Therapeutic Market, By Drug, 2021 - 2033, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Penicillin and Combinations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
  • Quinolones
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
  • Cephalosporin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
  • Azoles and Amphotericin B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
  • Nitrofurans
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
  • Other Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

5. Global Urinary Tract Infection Therapeutic Market, By Indication, 2021 - 2033, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Complicated UTI
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
  • Uncomplicated UTI
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
  • Other Indications
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

6. Global Urinary Tract Infection Therapeutic Market, By Geography, 2021 - 2033, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
  • Middle East and Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)

7. Competitive Landscape

  • Pfizer
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cipla Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Shionogi & Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Analyst Recommendation

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact